tailieunhanh - Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound

The dense stroma of pancreatic ductal adenocarcinomas is a major barrier to drug delivery. To increase the local drug difusion gradient, high doses of chemotherapeutic agent doxorubicin can be released from thermally-sensitive liposomes (ThermoDox®) using ultrasound-mediated hyperthermia at the tumour target. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN